BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Klotz L, Havla J, Schwab N, Hohlfeld R, Barnett M, Reddel S, Wiendl H. Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Ther Adv Neurol Disord 2019;12:1756286419836571. [PMID: 30967901 DOI: 10.1177/1756286419836571] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 13.7] [Reference Citation Analysis]
Number Citing Articles
1 Gold R, Fätkenheuer G, Hartung HP, Kleinschnitz C, Marks R, Maschke M, Bayas A, Löbermann M, Zettl UK, Wiendl H. Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets. Ther Adv Neurol Disord 2021;14:17562864211019598. [PMID: 34671422 DOI: 10.1177/17562864211019598] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ezabadi SG, Sahraian MA, Maroufi H, Shahrbaf MA, Eskandarieh S. Global assessment of characteristics of multiple sclerosis registries; A systematic review. Multiple Sclerosis and Related Disorders 2022. [DOI: 10.1016/j.msard.2022.103928] [Reference Citation Analysis]
3 Korsukewitz C, Reddel SW, Bar-Or A, Wiendl H. Neurological immunotherapy in the era of COVID-19 - looking for consensus in the literature. Nat Rev Neurol 2020;16:493-505. [PMID: 32641860 DOI: 10.1038/s41582-020-0385-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 13.0] [Reference Citation Analysis]
4 Brand A, De Angelis V, Vuk T, Garraud O, Lozano M, Politis D. Review of indications for immunoglobulin (IG) use: Narrowing the gap between supply and demand. Transfusion Clinique et Biologique 2021;28:96-122. [DOI: 10.1016/j.tracli.2020.12.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
5 Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Stangel M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Hunter ZR, Kallmann B, Kleinschnitz C, Klotz L, Leussink V, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber MS, Weber F, Zettl UK, Ziemssen T, Zipp F; die Multiple Sklerose Therapie Konsensus Gruppe (MSTKG). [Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)]. Nervenarzt 2021;92:773-801. [PMID: 34297142 DOI: 10.1007/s00115-021-01157-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Milo R. Therapies for multiple sclerosis targeting B cells. Croat Med J 2019;60:87-98. [PMID: 31044580 [PMID: 31044580 DOI: 10.3325/cmj.2019.60.87] [Cited by in Crossref: 21] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
7 Nally FK, De Santi C, McCoy CE. Nanomodulation of Macrophages in Multiple Sclerosis. Cells 2019;8:E543. [PMID: 31195710 DOI: 10.3390/cells8060543] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
8 Inojosa H, Proschmann U, Akgün K, Ziemssen T. The need for a strategic therapeutic approach: multiple sclerosis in check. Therapeutic Advances in Chronic Disease 2022;13:204062232110630. [DOI: 10.1177/20406223211063032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Rovira À, Auger C. Beyond McDonald: updated perspectives on MRI diagnosis of multiple sclerosis. Expert Rev Neurother 2021;:1-17. [PMID: 34275399 DOI: 10.1080/14737175.2021.1957832] [Reference Citation Analysis]
10 Boyko AN, Melnikov MV, Kozin MS, Kulakova OG. [The role of mitochondria in pathological mechanisms of innate immunity in multiple]. Zh Nevrol Psikhiatr Im S S Korsakova 2020;120:32-7. [PMID: 32844627 DOI: 10.17116/jnevro202012007232] [Reference Citation Analysis]
11 Otero-Romero S, Sánchez-Montalvá A, Vidal-Jordana A. Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment. Expert Rev Clin Immunol 2021;17:285-300. [PMID: 33543657 DOI: 10.1080/1744666X.2021.1886924] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Otero-Romero S, Rodríguez-García J, Vilella A, Ara JR, Brieva L, Calles C, Carmona O, Casanova V, Costa-Frossard L, Eichau S, García-Merino JA, Garcia-Vidal C, González-Platas M, Llaneza M, Martínez-Ginés M, Meca-Lallana JE, Prieto JM, Rodríguez-Antigüedad A, Tintoré M, Blanco Y, Moral E; en nombre del Grupo de enfermedades desmielizantes de la SEN. Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement. Neurologia (Engl Ed) 2021;36:50-60. [PMID: 32561334 DOI: 10.1016/j.nrl.2020.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
13 Zeng Y, Li Z, Zhu H, Gu Z, Zhang H, Luo K. Recent Advances in Nanomedicines for Multiple Sclerosis Therapy. ACS Appl Bio Mater 2020;3:6571-97. [DOI: 10.1021/acsabm.0c00953] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Wei W, Ma D, Li L, Zhang L. Progress in the Application of Drugs for the Treatment of Multiple Sclerosis. Front Pharmacol 2021;12:724718. [PMID: 34326775 DOI: 10.3389/fphar.2021.724718] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Yin JJ, He Y, An J, Miao Q, Sui RX, Wang Q, Yu JZ, Xiao BG, Ma CG. Dynamic Balance of Microglia and Astrocytes Involved in the Remyelinating Effect of Ginkgolide B. Front Cell Neurosci 2019;13:572. [PMID: 31969806 DOI: 10.3389/fncel.2019.00572] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
16 Ferreira CM, Vasconcelos-Pereira EF, Oliveira VM, Salgado PR, Domingos JA, Monreal MTFD, Guerra-Shinohara EM, Gubert VT. Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report. Medicine (Baltimore) 2021;100:e28246. [PMID: 34941096 DOI: 10.1097/MD.0000000000028246] [Reference Citation Analysis]
17 Masanneck L, Eichler S, Vogelsang A, Korsen M, Wiendl H, Budde T, Meuth SG. The STING-IFN-β-Dependent Axis Is Markedly Low in Patients with Relapsing-Remitting Multiple Sclerosis. Int J Mol Sci 2020;21:E9249. [PMID: 33291536 DOI: 10.3390/ijms21239249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Meng-Ru Z, Ruo-Xuan S, Ming-Yang Y, Tong T, Lei Z, Ying-Bo Y, Bao-Guo X. Antagonizing astrocytic platelet activating factor receptor-neuroinflammation for total flavone of epimedium in response to cuprizone demyelination. Int Immunopharmacol 2021;101:108181. [PMID: 34607229 DOI: 10.1016/j.intimp.2021.108181] [Reference Citation Analysis]
19 La Mantia L, Benedetti MD, Sant M, d'Arma A, Di Tella S, Lillini R, Mendozzi L, Marangi A, Turatti M, Caputo D, Rovaris M. Cancer risk for multiple sclerosis patients treated with azathioprine and disease-modifying therapies: an Italian observational study. Neurol Sci 2021. [PMID: 33791892 DOI: 10.1007/s10072-021-05216-z] [Reference Citation Analysis]
20 Otero-Romero S, Ascherio A, Lebrun-Frénay C. Vaccinations in multiple sclerosis patients receiving disease-modifying drugs. Curr Opin Neurol 2021;34:322-8. [PMID: 33709979 DOI: 10.1097/WCO.0000000000000929] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
21 Hundehege P, Cerina M, Eichler S, Thomas C, Herrmann AM, Göbel K, Müntefering T, Fernandez-Orth J, Bock S, Narayanan V, Budde T, Speckmann EJ, Wiendl H, Schubart A, Ruck T, Meuth SG. The next-generation sphingosine-1 receptor modulator BAF312 (siponimod) improves cortical network functionality in focal autoimmune encephalomyelitis. Neural Regen Res 2019;14:1950-60. [PMID: 31290453 DOI: 10.4103/1673-5374.259622] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
22 Sriwastava S, Kataria S, Srivastava S, Kazemlou S, Gao S, Wen S, Saber H, Tripathi R, Sheikh Z, Peterson S, Gwinn R, Bernitsas E. Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis. J Neuroimmunol 2021;360:577721. [PMID: 34547511 DOI: 10.1016/j.jneuroim.2021.577721] [Reference Citation Analysis]
23 Thompson KK, Tsirka SE. Guanabenz modulates microglia and macrophages during demyelination. Sci Rep 2020;10:19333. [PMID: 33168944 DOI: 10.1038/s41598-020-76383-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Mirabella M, Annovazzi P, Brownlee W, Cohen JA, Kleinschnitz C, Wolf C. Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate? Front Neurol 2022;13:844873. [DOI: 10.3389/fneur.2022.844873] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Havla J, Hohlfeld R. Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair. Neurotherapeutics 2022. [PMID: 35289375 DOI: 10.1007/s13311-022-01214-x] [Reference Citation Analysis]
26 Filippi-Arriaga F, Riera-Arnau J, Rodríguez-Acevedo B, Bosch Ferrer M. Progressive multifocal leukoencephalopathy in the era of new disease-modifying treatments for multiple sclerosis. Med Clin (Barc) 2021;156:509-14. [PMID: 33431183 DOI: 10.1016/j.medcli.2020.10.015] [Reference Citation Analysis]
27 Pawlitzki M, Zettl UK, Ruck T, Rolfes L, Hartung HP, Meuth SG. Merits and culprits of immunotherapies for neurological diseases in times of COVID-19. EBioMedicine 2020;56:102822. [PMID: 32535547 DOI: 10.1016/j.ebiom.2020.102822] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
28 Seccia R, Gammelli D, Dominici F, Romano S, Landi AC, Salvetti M, Tacchella A, Zaccaria A, Crisanti A, Grassi F, Palagi L. Considering patient clinical history impacts performance of machine learning models in predicting course of multiple sclerosis. PLoS One 2020;15:e0230219. [PMID: 32196512 DOI: 10.1371/journal.pone.0230219] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
29 Nicholas JA, Gudesblatt M, Garabedian M, Belviso N, Shen C, Geremakis C, Shankar SL, Mendoza JP, Lewin JB. Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab. Multiple Sclerosis and Related Disorders 2022. [DOI: 10.1016/j.msard.2022.103921] [Reference Citation Analysis]
30 Salinas VH, Stüve O. Systems Approaches to Unravel T Cell Function and Therapeutic Potential in Autoimmune Disease. J Immunol 2021;206:669-75. [PMID: 33526601 DOI: 10.4049/jimmunol.2000954] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Wens I, Janssens I, Derdelinckx J, Meena M, Willekens B, Cools N. Made to Measure: Patient-Tailored Treatment of Multiple Sclerosis Using Cell-Based Therapies. Int J Mol Sci 2021;22:7536. [PMID: 34299154 DOI: 10.3390/ijms22147536] [Reference Citation Analysis]
32 Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Kallmann B, Kleinschnitz C, Klotz L, Leussink VI, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F; ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG). Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord 2021;14:17562864211039648. [PMID: 34422112 DOI: 10.1177/17562864211039648] [Reference Citation Analysis]
33 Smith TE, Kister I. Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies. Curr Neurol Neurosci Rep 2021;21:36. [PMID: 34009478 DOI: 10.1007/s11910-021-01117-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Boyko AN, Sivertseva SA, Chemakina DS, Spirin NN, Bykova OV, Guseva ME. [Vaccination and multiple sclerosis at the present stage]. Zh Nevrol Psikhiatr Im S S Korsakova 2021;121:44-8. [PMID: 34387445 DOI: 10.17116/jnevro202112107244] [Reference Citation Analysis]
35 Graf J, Albrecht P, Goebels N, Aktas O, Hartung HP. [Ocrelizumab for treatment of multiple sclerosis]. Nervenarzt 2020;91:722-34. [PMID: 32524163 DOI: 10.1007/s00115-020-00937-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Liebmann M, Korn L, Janoschka C, Albrecht S, Lauks S, Herrmann AM, Schulte-Mecklenbeck A, Schwab N, Schneider-Hohendorf T, Eveslage M, Wildemann B, Luessi F, Schmidt S, Diebold M, Bittner S, Gross CC, Kovac S, Zipp F, Derfuss T, Kuhlmann T, König S, Meuth SG, Wiendl H, Klotz L. Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity. Brain 2021;144:3126-41. [PMID: 34849598 DOI: 10.1093/brain/awab307] [Reference Citation Analysis]
37 Kartau M, Sipilä JO, Auvinen E, Palomäki M, Verkkoniemi-Ahola A. Progressive Multifocal Leukoencephalopathy: Current Insights. Degener Neurol Neuromuscul Dis 2019;9:109-21. [PMID: 31819703 DOI: 10.2147/DNND.S203405] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
38 Maniscalco GT, Brescia Morra V, Florio C, Lus G, Tedeschi G, Cianfrani M, Docimo R, Miniello S, Romano F, Sinisi L, Spitaleri DLA, Longo G, Trama U, Triassi M, Fasm Group, Scavone C, Capuano A. Preliminary Results of the FASM Study, an On-Going Italian Active Pharmacovigilance Project. Pharmaceuticals (Basel) 2020;13:E466. [PMID: 33333889 DOI: 10.3390/ph13120466] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Zingaropoli MA, Pasculli P, Iannetta M, Perri V, Tartaglia M, Crisafulli SG, Merluzzo C, Baione V, Mazzochi L, Taglietti A, Pauri F, Frontoni M, Altieri M, Gaeta A, Antonelli G, Conte A, Mastroianni CM, Ciardi MR. Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: A three-year observational cohort study. Mult Scler J Exp Transl Clin 2022;8:20552173211065731. [PMID: 35003758 DOI: 10.1177/20552173211065731] [Reference Citation Analysis]
40 Zanghì A, D'Amico E, Patti F. Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment. Expert Rev Neurother 2020;20:771-82. [PMID: 31971026 DOI: 10.1080/14737175.2020.1721282] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Brown J, Everett C, Barragan JA, Vargas-medrano J, Gadad BS, Nichols F, Cervantes JL. Interferon-β and Fingolimod Control Microglial Inflammatory Cell Polarization in Response to Multiple Sclerosis-associated Bacterial Ligand 654. Archives of Medical Research 2021. [DOI: 10.1016/j.arcmed.2021.11.002] [Reference Citation Analysis]
42 Giovannoni G, Mathews J. Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review. Neurol Ther 2022;11:571-95. [PMID: 35318617 DOI: 10.1007/s40120-022-00339-7] [Reference Citation Analysis]
43 Pasku D, Shah S, Aly A, Quraishi NA. Rare, post-periodontitis spondylodiscitis caused by Fusobacterium nucleatum in a patient with multiple sclerosis: challenge of diagnosis and treatment. BMJ Case Rep 2021;14:e239664. [PMID: 33737279 DOI: 10.1136/bcr-2020-239664] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Tenembaum S, Yeh EA; Guthy-Jackson Foundation International Clinical Consortium (GJCF-ICC). Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis. Front Pediatr 2020;8:339. [PMID: 32671002 DOI: 10.3389/fped.2020.00339] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
45 Moiola L, Barcella V, Benatti S, Capobianco M, Capra R, Cinque P, Comi G, Fasolo MM, Franzetti F, Galli M, Gerevini S, Meroni L, Origoni M, Prosperini L, Puoti M, Scarpazza C, Tortorella C, Zaffaroni M, Riva A. The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement. Mult Scler 2021;27:331-46. [PMID: 32940121 DOI: 10.1177/1352458520952311] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
46 Paolicelli D, Manni A, Iaffaldano A, Trojano M. Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis. CNS Drugs 2020;34:65-92. [PMID: 31898276 DOI: 10.1007/s40263-019-00691-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
47 Lin WW, Lu YC, Chuang CH, Cheng TL. Ab locks for improving the selectivity and safety of antibody drugs. J Biomed Sci 2020;27:76. [PMID: 32586313 DOI: 10.1186/s12929-020-00652-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]